Abstract: A polypeptide compound includes a structure represented by General Formula (I): KX2X3RX5KX7X8RX10HSY (SEQ ID NO:3)-R1 (I). X2 is selected from the group consisting of Lys, HoLys, Dap, DAB, Cit, Orn, D-Lys, D-HoLys, D-Dap, D-DAB, D-Cit, D-Orn, and Lys whose side-chain amino group is modified by Z1; X3 and X5 are each independently selected from the group consisting of Asn, Asp, D-Asn, and D-Asp; X7 is selected from the group consisting of Ile, Leu, Val, Tel, D-Ile, D-Leu, D-Val, and D-Tel; X8 is selected from the group consisting of Arg, HomoArg, D-Arg, and D-HomoArg; and X10 is selected from the group consisting of Glu, Gln, D-Glu, and D-Gln.

Abstract: Modified flavone compounds are compounds of formula (I), or a pharmaceutically acceptable stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, cocrystal, metabolite, salt, deuterated form, or prodrug thereof. The modified flavone compounds can serve as small-molecule agonists for the tropomyosin receptor kinase B (TrkB receptor), and can effectively mimic the action of brain-derived neurotrophic factor (BDNF) to protect neurons, thereby aiding in the treatment of neurological and psychiatric diseases.

Abstract: Disclosed in the present invention are 7-azaindole compounds, a preparation method therefor, and the use thereof, belonging to the field of drug synthesis. The present invention particularly relates to 7-azaindole compounds containing pyrazole or indole substitution represented by general formula (I), a preparation method therefor and the use thereof in medicine. The compounds of the present invention alleviate cancer cachexia skeletal muscle atrophy by means of inhibiting ActRIIB protein in the MSTN pathway, thereby achieving a remarkable anti-cancer-cachexia effect. Experimental results show that the compounds have good anti-cachexia activity and thus can be further used for preparing novel anti-cachexia drugs.

Abstract: This application provides a scraper conveyor straightening method based on a rolling time-domain control concept. The scraper conveyor straightening method includes an execution space, a deduction space, and a prediction space.

Abstract: This application provides example phase detectors, methods thereof, clock and data recovery circuits, and electronic devices. One example phase detector includes a data integrator, coupled to a sampling clock end and configured to integrate input data based on a signal at a sampling clock end, a data sampling comparator, configured to perform sampling comparison between output of the data integrator and a specified value, a transition edge integrator, coupled to the sampling clock end and configured to integrate on the input data based on the signal at the sampling clock end, a transition edge sampling comparator, configured to perform sampling comparison between output of the transition edge integrator and the specified value, and a logic processor, configured to perform logic processing on a comparison result of the data sampling comparator and a comparison result of the transition edge sampling comparator, and output a lead or lag processing result.

Abstract: The present disclosure provides a method for preparing lithium iron phosphate from ferric hydroxyphosphate, including: purifying ferrous sulfate to form a ferrous sulfate solution, adding hydrogen peroxide, phosphoric acid, an ammonium dihydrogen phosphate solution and ammonia water into the ferrous sulfate solution and then reacting to form a mixed slurry, holding the mixed slurry at a temperature for a period of time, and then washing with water and subjecting to press filtration to form ferric hydroxyphosphate precursors with different iron-phosphorus ratios; then flash drying, sintering at a high temperature, and pulverizing to obtain ferric hydroxyphosphate precursors with different iron-phosphorus ratios and different specific surface areas.

Abstract: A site effect simulator, including a site effect simulator base plate, where counter-force pillars are vertically arranged at diagonals of the site effect simulator base plate, the counter-force walls are connected to counter-force pillars along two sides of the site effect simulator base plate, a plurality of single-layer soil boxes are arranged at the inner side of the site effect simulator base plate, wave-absorbing materials are arranged inside single-layer soil boxes, and sliding panels are arranged at an upper side and a lower side of each single-layer soil box. The present disclosure does not need to rely on other counter-force frames, has the characteristics of flexible use, and can be randomly placed, and the height can be adjusted randomly. With a servo hydraulic actuator with three directions and six degrees of freedom, seismic simulation tests can be realized independently.

Abstract: The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is an antagonist of/an inhibitor of signaling, which is based on an interaction of TNF with its cognate receptor (TNFR), wherein the antagonisation or the inhibition of TNF or its cognate receptor prevents, reduces, or blocks TNF/TNFR mediated signalling. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: A delay control device, a delay control method and an electronic apparatus are provided. The delay control device includes: a trigger port, configured to receive a trigger signal; a first interface; a second interface; a control module, configured to disconnect connection between the first interface and the second interface in response to a case that the trigger port receives the trigger signal; and a timing module, configured to carry out timing for a duration; the control module is further configured to connect the first interface and the second interface in response to a case that the timing module completes timing of the duration. The delay control device can achieve a delay control function, prevent program confusion, improve efficiency and save cost.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.